MD Anderson and Amgen announce agreement to develop BiTE® therapies for myelodysplastic syndrome

The University of Texas MD Anderson Cancer Center and Amgen have announced a research collaborative agreement focusing on Amgen's bispecific T cell engager (BiTE®) antibody constructs, an immunotherapy that serves as a "bridge" between T cells and cancer cells.
Source: M. D. Anderson Cancer Center - News Releases - Category: Cancer & Oncology Source Type: news